All In Biotech

Drug Trial Radar · NCT05908409

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

A Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (CASSANDRA)

Last checked: Nov 19, 2026Latest source record: May 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

37

Planned (sponsor's estimate)

Start

Jun 5, 2023

Primary completion

Dec 22, 2025

Study completion Mar 22, 2026

Sponsor

Lead sponsor
IDP Discovery Pharma S.L.Industry
Sponsor type
Industry
First posted
Jun 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aims of this 2-part study are: * Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), diffuse large B cell lymphoma not otherwise specified (DLBCL-NOS), high-grade B cell lymphoma with double or triple hit rearrangement (HGBL-DH/TH) and HGBL-NOS, and chronic lymphocytic leukemia (CLL). * Phase II: To evaluate the overall response rate (ORR), duration of response (DoR), time to progression (TTP), progression-free survival (PFS), event-free survival (EFS) and Overall survival (OS), in patients with MM, DLBCL-NOS, HGBL-DH/TH, HGBL-NOS or CLL treated with IDP-121 at the recommended Phase 2 Dose (RP2D).

Conditions

  • Multiple Myeloma (MM)
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Double Hit Lymphoma
  • High Grade B-Cell Lymphoma, Not Otherwise Specified
  • Chronic Lymphocytic Leukemia (CLL)
  • Triple Hit Lymphoma

Interventions

  • IDP-121Drug

    IDP-121 is a new chemical entity specifically designed to directly target cMyc protein that has demonstrated activity in multiple liquid and solid tumor cell lines and preclinical animal models

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Dose EscalationTime frame: Through 1 treatment cycle (each cycle is 28 days)
  2. Phase 1: Dose EscalationTime frame: Through 12 treatment cycles (each cylce is 28 days) or until End of Treatment, whatever occurs first
  3. Phase 2: Expansion PhaseTime frame: Based on iwCLL 20181, IMWG 20162, and the Lugano 20143 criteria for CLL, MM and Lymphomas, respectively; assessed at the end of study (12 months)

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitari Vall d'hebron

    Barcelona, Spain · Recruiting

  • Hospital Durán i Reynals - ICO L´Hospitalet

    Barcelona, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Universitario La Paz

    Madrid, Spain · Recruiting

  • Hospital Universitario Puerta de Hierro

    Madrid, Spain · Recruiting

  • Hospital Clínico Universitario Virgen de la Arrixaca

    Murcia, Spain · Recruiting

  • Hospital Universitario Virgen del Rocio

    Seville, Spain · Recruiting

  • Hospital de Clinico Universitario de Valencia

    Valencia, Spain · Recruiting

  • Hospital Universitario Miguel Servet

    Zaragoza, Spain · Recruiting

  • Hospital Universitario Marques de Valdecilla

    Santander, Cantabria, Spain · Recruiting

  • Hospital Universitario de Salamanca

    Salamanca, Castille and León, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.